Immunocore/$IMCR
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
- Ticker
- $IMCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 524
- Headquarters
- Abingdon, United Kingdom
- Website
- www.immunocore.com
Immunocore Metrics
BasicAdvanced
$1.9B
-
-$0.36
0.74
-
Price and volume
Market cap
$1.9B
Beta
0.74
52-week high
$40.71
52-week low
$27.56
Average daily volume
456K
Financial strength
Current ratio
4.469
Quick ratio
4.148
Long term debt to equity
103.157
Total debt to equity
103.611
Interest coverage (TTM)
-0.23%
Profitability
EBITDA (TTM)
0.756
Gross margin (TTM)
32.87%
Net profit margin (TTM)
-4.20%
Operating margin (TTM)
-0.66%
Effective tax rate (TTM)
-561.57%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-0.16%
Return on equity (TTM)
-4.47%
Valuation
Price to revenue (TTM)
4.4
Price to book
4.59
Price to tangible book (TTM)
4.59
Price to free cash flow (TTM)
-46.062
Free cash flow yield (TTM)
-2.17%
Free cash flow per share (TTM)
-0.812
Growth
Revenue change (TTM)
20.95%
Earnings per share change (TTM)
-13.06%
3-year revenue growth (CAGR)
25.19%
3-year earnings per share growth (CAGR)
-34.44%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Immunocore News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.